About Anjan Drug
Anjan Drug is a Healthcare company based in Chennai (India) founded in 1990 by C Kalaichelvan, and was acquired by PAG in October 2020. Active pharmaceutical ingredients for CNS disorders are manufactured. Anjan Drug has raised $5.28 million across 1 funding round from investors including Evolvence, C Kalaichelvan and K Lalitha. The company has 297 employees. Anjan Drug was last valued at $9.07 million in June 2009. Its Indian entity Anjan Drug Private Limited reported revenue of ₹293 Cr. Anjan Drug offers products and services including Valproic Acid, Sodium Valproate, Divalproex Sodium, Magnesium Valporate, and Gabapentin. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 1990 in Chennai, India, active pharmaceutical ingredients are produced by Anjan Drug within the pharmaceutical sector, with operations centered on central nervous system treatments. Epilepsy drugs are manufactured as a US-FDA approved producer, adhering to US, European, and British Pharmacopeia standards. Approvals for US and Canadian DMFs, along with a European Certificate of Suitability, have been secured. Clients such as Abbott, Sanofi-Aventis, Mylan, and Actavis are served.
- Headquarters Chennai, India
- Employees 297
- Founders C Kalaichelvan
- Stage Acquired
- SectorsHealthcare
- Website anjandrug.net
- Social LinkedIn
- Acquired by PAG (Oct 2020)
- Legal Name Anjan Drug Private Limited
- Date of Incorporation 01 Aug, 1990
- Jurisdiction Chengalpattu Dt, Tamil Nadu, India
Associated legal entities of Anjan Drug
Anjan Drug operates through Anjan Drug Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Anjan Drug Private Limited CIN U24231TN1990PTC019461 | Active | 01 Aug 1990 | Chengalpattu, Tamil Nadu | ₹293 Cr | 297 | 9 | View details |
Products & Services of Anjan Drug
Anjan Drug offers a comprehensive portfolio of products and services, including Valproic Acid, Sodium Valproate, Divalproex Sodium, Magnesium Valporate, and Gabapentin.
Active ingredient used in pharmaceutical treatments for neurological disorders.
Key component for antiepileptic and mood-stabilizing medications.
Compound for managing seizures and bipolar disorder in drugs.
Ingredient in formulations for epilepsy and psychiatric conditions.
Active substance for treating nerve pain and seizures.
Funding Insights of Anjan Drug
Anjan Drug has successfully raised a total of $5.28M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.28 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.28M
- Total Rounds 1
- Last Round Series A — $5.28M
- First Round $5.28M
(Jun 2009)
- Investors Count 3
All 1 funding rounds of Anjan Drug with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2009 | $5.28M | Series A | $9.07M | Evolvence |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2009 | $9.07M | •••••••• |
Last known valuation $9.07M (Jun 2009). 6 investors in total: 4 institutional and 2 angel.
Investors in Anjan Drug
Anjan Drug has secured backing from 6 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Evolvence, C Kalaichelvan and K Lalitha.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Alternative investment firm | pag.com | |||
Private equity investments are managed across multiple sectors. | samaracapital.com | Mumbai, India | ||
Private equity investments in India are managed by CX Partners. | cxpartners.in | Delhi, India | ||
Holding company focused on asset management, education and retail | 2001 | evolvence.com | Dubai, United Arab Emirates | |
CK C Kalaichelvan | unknown_be7dc5918fb2472f9 | |||
KL K Lalitha | unknown_f23605dfca9348d4b |
Investor details for Anjan Drug
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Anjan Drug Private Limited (Anjan Drug)
Anjan Drug Private Limited is the primary company behind Anjan Drug. The board of Anjan Drug Private Limited currently have 8 directors; the longest-serving is Chinnannan Kalaichelvan, appointed in 1990. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Chinnannan Kalaichelvan DIN 00742880 | Director | 01 Aug 1990 | 36 yrs 3 mo | Anjan Drug Private Limited |
| Vivek Chhachhi DIN 00496620 | Nominee Director | 09 Oct 2020 | 6 yrs 1 mo | Anjan Drug Private Limited |
| Pagadala Baskarannarayanan DIN 09754875 | Director | 11 Jan 2023 | 3 yrs 9 mo | Anjan Drug Private Limited |
| Anil Khubchandani DIN 09209485 | Director | 12 Oct 2023 | 3 yrs | Anjan Drug Private Limited |
| Lakshay Kataria DIN 08345477 | Additional Director | 01 Apr 2025 | 1 yr 7 mo | Anjan Drug Private Limited |
| Sumit Mohan Nadgir DIN 07619675 | Director | 01 May 2025 | 1 yr 6 mo | Anjan Drug Private Limited |
| Santosh Kumar Mahil DIN 07584287 | Director | 26 Jun 2025 | 1 yr 4 mo | Anjan Drug Private Limited |
| Devi Thumati Krishnaraj DIN 09717731 | Officer in default | 16 Jul 2025 | 1 yr 3 mo | Anjan Drug Private Limited |
People of Anjan Drug
11 people are tracked at Anjan Drug (2 in leadership, 9 in team); the tracked headcount is 297.
| Name | Role | Group |
|---|---|---|
C Kalaichelvan | Founder | Leadership |
Lakshmi Narayanan | Head Of Finance | Leadership |
Karthik R | Engineering Manager | Team |
Naveen Kumar | Junior Engineer | Team |
Gopi Vetrivel | Health Safety Environment Engineer | Team |
Bhuvanesh Yokesh | Electrical Engineer | Team |
Bala Elumalai | Junior Engineer | Team |
Gopinath K | Junior Engineer | Team |
Ranjith Kumar | Junior Executive | Team |
Susidharan M | Graduate Engineer Trainee-process | Team |
Gowtham R | Associate Manager | Team |
Complete people profiles for Anjan Drug
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Anjan Drug
Figures of Anjan Drug Private Limited, the primary company behind Anjan Drug, for FY 2025. Revenue was ₹293 Cr (-14% year on year). Net profit was ₹49.98 Cr (17% margin). EBITDA was ₹82.64 Cr (28% margin). Revenue has grown at a compounded annual rate of +16% over three years.
- ₹293 CrRevenue · FY 2025 · -14% YoY
- ₹49.98 CrNet profit · 17% margin
- ₹82.64 CrEBITDA · 28% margin
- ₹5.88 CrPaid-up capital
- 297Employees (provident fund records)
- +16%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Anjan Drug Private Limited are on its company page.
Detailed financial statements for Anjan Drug
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Anjan Drug
4 dated milestones of Anjan Drug across 30 years, from founding to its latest funding, stage changes and deals.
- Founded Anjan Drug is founded.
- Funding First funding round of $5.3M.
- Milestone Reaches Minicorn status.
- Exit Acquired by PAG.
Competitors of Anjan Drug
Anjan Drug has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed competitors of Anjan Drug
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Anjan Drug
The website of Anjan Drug (anjandrug.net) receives about 1K visits a month.
- Monthly visits1K
▲ 1.1% vs previous month
Websites whose visitors overlap most with Anjan Drug. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| proventuslife.com | 100% | View details | |||
bulkdrugsdirectory.com | bulkdrugsdirectory.com | 77% | #9,524,285 | – |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Anjan Drug (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anjan Drug
Complete news archive for Anjan Drug
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anjan Drug
Anjan Drug was founded in 1990 and raised its 1st funding round 19 years after it was founded.
Anjan Drug is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Anjan Drug is a funded company, having raised a total of $5.28M across 1 funding round to date. The company's 1st funding round was a Series A of $5.28M, raised on Jun 2009.
Anjan Drug has 297 employees.
The primary company behind Anjan Drug, Anjan Drug Private Limited, reported revenue of ₹293 Cr for FY 2025, down 14% year on year.
Founded in 1990 in Chennai, India, active pharmaceutical ingredients are produced by Anjan Drug within the pharmaceutical sector, with operations centered on central nervous system treatments. Epilepsy drugs are manufactured as a US-FDA approved producer, adhering to US, European, and British Pharmacopeia standards. Approvals for US and Canadian DMFs, along with a European Certificate of Suitability, have been secured. Clients such as Abbott, Sanofi-Aventis, Mylan, and Actavis are served.
Anjan Drug's top competitors include Laurus Labs, Symbiotec and SeQuent.
Anjan Drug offers Valproic Acid, Sodium Valproate, Divalproex Sodium, Magnesium Valporate, and Gabapentin.
Anjan Drug has 6 investors. Key investors include Evolvence, C Kalaichelvan, K Lalitha, PAG, and Samara Capital.
The valuation of Anjan Drug is $9.07M as of Jun 2009.
Anjan Drug operates through Anjan Drug Private Limited.
Yes. Anjan Drug was acquired by PAG in October 2020.